TRAITEMENT DU CANCER COLORECTAL ET MISES À JOUR SUR LA RECHERCHE CLINIQUE
Month Ending September 15th, 2022
The following colorectal cancer treatment and research updates extend from August 18,, 2022, to September 15,, 2022, inclusive and are intended for informational purposes only.
Ce contenu n'est pas destiné à se substituer à un avis médical professionnel. Consultez toujours votre médecin traitant ou les conseils d'un professionnel de la santé qualifié pour toute question concernant votre santé ou un problème médical. Ne négligez jamais l'avis d'un professionnel de la santé et ne tardez jamais à le solliciter en raison d'un élément que vous avez lu sur ce site web.
1. Essai clinique LEAP de phase II pour le traitement du CCRm
2. TRK Fusion Cancer and How to Test for It
3. A Phase II, Open-Label, Multicentre, Study of an Immunotherapeutic Treatment for the MSI High CRC Metastatic Population
4. Phase III Study at the Odette Cancer Centre Comparing Arfolitixorin vs. Leucovorin: Both in Combination with 5FU, Oxaliplatin, and Bevacizumab in Patients with Advanced CRC
5. Trial for CRC Drug Reaches Primary Endpoint
6. Amgen’s KRAS-Targeting Lumakras Combo Heads into Late-Stage CRC Testing
7. Efficacy, Safety and Prognostic Factors in Patients with Refractory mCRC Treated with Trifluridine/Tipiracil plus Bevacizumab in a Real-World Setting
8. Cardiff Oncology Launches Phase II Trial of PLK1 Inhibitor in RAS-Mutated Colon Cancer
9. Neoadjuvant Nivolumab/Ipilimumab Shows Unprecedented Pathologic Responses in dMMR Colon Cancer
10. Hepatic Artery Infusion Pump (HAIP) Chemotherapy Program – Sunnybrook Hospital
11. Living Donor Liver Transplantation for Unresectable CRC Liver Metastases
12. Study Offered at the Odette Cancer Centre to Treat Recurrent Rectal Cancer
13. Trends in the Incidence of Young-Onset CRC with a Focus on Years Approaching Screening Age
14. Guardant Debuts its First Cancer Screening Blood Test for Catching Colorectal Tumors
15. Colorectal Sessile Serrated Lesion Detection Using Linked Colour Imaging
16. Early-Onset CRC Incidence, Staging, and Mortality in Canada: Implications for Population-Based Screening
17. Ryan Reynolds Undergoes ‘Life-Saving’ Colonoscopy — And It Was All Caught on Video
18. Young Adult CRC Clinic Available at Sunnybrook Hospital
19. CCRAN’s Partnership with “Count Me In”
20. Patients and Caregivers Needed to Help Shape Early Research for a CRC Therapy
21. Under 50 National Colorectal Cancer Information/Support Group Leader
22. EXercise for Cancer to Enhance Living Well (EXCEL) Study
23. Ultra-processed Foods Linked to Cancer and Early Death
24. New NCCN CRC Guidelines Recommend Genetic Testing for All Diagnosed Patients
MÉDICAMENTS / THÉRAPIES SYSTÉMIQUES
1. Phase II LEAP Clinical Trial For mCRC (Sept.10/21)
Le but de cette étude est de déterminer la sécurité et l'efficacité de la thérapie combinée avec le pembrolizumab (MK-3475) et Levantine la levantine (E7080/MK-7902) chez les patients atteints de cancer du sein triple négatif (TNBC), de cancer des ovaires, de cancer gastrique, cancer colorectal (CCR), glioblastoma (GBM), or biliary tract cancers (BTC). Participants will be enrolled in initial tumor-specific cohorts, which will be expanded if adequate efficacy is determined. The trial is available at the Odette Cancer Centre and at the Princess Margaret Cancer Centre in Toronto as well as the following Centres throughout Canada: Abbotsford, BC; Winnipeg, MB; CHU de Quebec. For information, visit the link below.
2. TRK Fusion Cancer and How to Test for It (Sept.16/21)
3. A Phase II, Open-label, Multicenter, Study of an Immunotherapeutic Treatment for the MSI High CRC Metastatic Population (Sept.16/21)
L'objectif de cette étude est d'examiner l'efficacité du vaccin DPX-Survivac en combinaison avec les médicaments cyclophosphamide et l'immunothérapie Pembrolizumab in patients with solid cancers who are identified to be MSI-High. All patients will receive combination therapy of DPX-Survivac, cyclophosphamide, and pembrolizumab. Patients participating will know which treatment they are receiving. The trial is currently hosted at the Odette Cancer Centre, and a new site is opening at Mt. Sinai Hospital.
4. Phase III Study at the centre de cancérologie Odette Comparing Arfolitixorin vs. Leucovorin in Combination with 5FU, Oxaliplatin and Bevacizumab in Patients with Advanced CRC (Aug.16/21)
The purpose of this study is to look at the effectiveness of the drug Arfolitixorin in combination with 5-fluorouracil (5FU), oxaliplatin, and bevacizumab in patients with colorectal cancer (CRC). Patients with advanced/metastatic CRC who meet certain criteria may be able to participate. There will be two groups of patients participating in this study;
- un groupe recevra de L'arfolitixorine en combinaison avec du 5FU), de l'oxaliplatine et du bevacizumab,
- tandis que l'autre groupe recevra le médicament Leucovorin en combinaison avec le 5FU, l'oxaliplatine et le bevacizumab (norme de soins).
Le médecin et le personnel de l'étude ne sauront pas dans quel groupe se trouve un patient. Les patients seront répartis au hasard pour recevoir l'un ou l'autre traitement.
A propos Arfolitixorin:
L'arfolitixorine is Isofol’s proprietary drug candidate being developed to increase the efficacy of standard of care chemotherapy for advanced CRC. The drug candidate is currently being studied in a global Phase 3 clinical trial. As the key active metabolite of the widely used folate-based drugs, arfolitixorin can potentially benefit all patients with advanced CRC, as it does not require complicated metabolic activation to become effective.
Traiter les patients atteints de cancer avec de l'arfolitixorine - Les objectifs :
- When treating CRC, for example, arfolitixorin is administered in combination with 5-FU to increase cell mortality in circulating cancer cells and in cancerous tumours.
- Arfolitixorin is administered in conjunction with rescue therapy after high-dose treatment with the cytotoxic agent, methotrexate, in order to suppress the cytotoxic effect in surrounding healthy tissue. The treatment is used for certain types of cancer, such as osteosarcoma, a type of bone cancer. This involves administering arfolitixorin separately, 24 hours after the chemotherapy.
5. Trial for CRC Drug Reaches Primary Endpoint (Aug.17/22)
A new therapy for metastatic colorectal cancer (mCRC) that has been granted fast track designation by the U.S. Food and Drug Administration has met its primary endpoint of overall survival in a phase 3 clinical trial, the FRESCO 2 study. The study is an international clinical trial for patients with advanced, refractory mCRC.
By meeting the primary endpoint of overall survival with a secondary endpoint of progression-free survival, fruquintinib provides a significant potential new option for refractory CRC patients. As an oral agent, fruquintinib also provides added convenience for patients. Based on fruquintinib’s profile, there will likely be further exploration in future clinical trials in different settings. Full results will be submitted for presentation at an upcoming medical meeting.
6. Amgen’s KRAS G12C -Targeting Lumakras Combo Heads into Late-Stage CRC Testing (Sept.16/21)
In a phase 1b/2 study, a combination of Amgen’s KRAS inhibitor Lumakras and its EGFR inhibitor Vectibix showed encouraging effectiveness and safety results in patients with KRAS G12C-mutated colorectal cancer (CRC). The early trial enrolled 31 patients who were heavily pretreated—having had a median of two prior therapies—in its dose exploration and dose expansion cohorts for the Lumakras-Vectibix combo. The meds triggered a response in 27% among the 26 patients in an efficacy analysis group, which included five patients whose disease progressed after previous treatment with Lumakras as a solo therapy. The results for the combo therapy were “much higher” than the 9.7% response Lumakras managed to generate alone. Overall, the disease control rate for the combo came in at 81%.
7. Efficacy, Safety and Prognostic Factors in Patients with Refractory mCRC Treated with Trifluridine/Tipiracil (Lonsurf) plus Bevacizumab in a Real-World Setting (Aug.26/22)
In a retrospective, observational study, researchers evaluated the efficacy and safety of trifluridine/tipiracil (TAS-102) plus bevacizumab in treating refractory metastatic colorectal cancer (mCRC). Patients refractory or intolerant to standard therapies received TAS-102 (30–35 mg/m2 twice daily on days 1–5 and days 8–12 every 28 days) plus bevacizumab 5 mg/kg on days 1 and 15. The majority of patients (68.6%) were receiving TAS-102 plus bevacizumab as third-line treatment. Patients received a median of 4 (range 2–15) cycles of treatment. Among 31 patients evaluable for response (88.6%), overall response rate and disease control rate were 3.2% and 51.6%, respectively. After a median 11.6 months’ follow-up, median progression-free survival was 4.3 months and median overall survival was 9.3 months. Thus, this real-world study confirms the efficacy and safety of TAS-102 plus bevacizumab in patients with refractory mCRC in routine clinical practice, with survival and tolerability outcomes that were generally consistent with previous clinical and real-world studies of patients in this setting.
8. Cardiff Oncology Launches Phase II Trial of PLK1 Inhibitor in RAS-Mutated Colon Cancer (Sept.13/22)
Cardiff Oncology said it will conduct a Phase II trial of its PLK1 inhibitor onvansertib with standard-of-care FOLFIRI and Genentech’s Avastin (bevacizumab) in second-line metastatic colorectal cancer (mCRC) bearing RAS mutations.
The trial, named ONSEMBLE, will test the safety and efficacy of onvansertib in about 150 patients who will be randomized to one of three arms. One arm will receive 20 mg onvansertib with FOLFIRI and Avastin. A second group of patients will receive 30 mg onvansertib with FOLFIRI and Avastin. And a third group will receive FOLFIRI and Avastin only. The onvansertib doses will be given on days 1-5 and 15-19 of 28-day treatment cycles. The primary endpoint of the trial will be objective response rate, with progression-free survival and duration of response as secondary endpoints.
Data from a recent Phase Ib/II trial provided encouragement for the company to proceed with a Phase II trial. In that similarly designed trial, the median duration of response in 35 evaluable patients was 11.7 months, and the overall response was 35%, including responses in multiple KRAS variants. The median progression-free survival was 9.3 months. The company said those results were “well above” historical control trials in mCRC. If all goes well, Cardiff hopes to apply for accelerated approval in second-line KRAS- or NRAS-mutated mCRC.
9. Neoadjuvant Nivolumab/Ipilimumab Shows Unprecedented Pathologic Responses in dMMR Colon Cancer (Sept.11/22)
According to data presented at the 2022 ESMO Congress, results from the NICHE-2 trial showed major pathologic responses (MPRs) in 95% of patients with mismatch repair deficient (dMMR) colon cancer after only 4 weeks of treatment with nivolumab plus ipilimumab. Contrastingly, data from neoadjuvant chemotherapy in this same patient population had only 7% pathologic responses. The non-randomized, multicenter NICHE-2 trial was initiated by investigators after 32 patients with nonmetastatic dMMR colon cancer in the NICHE-1 trial showed 100% pathologic responses and 60% pathologic complete responses (pCRs) to an immune checkpoint blockade. Additionally in the NICHE-2 trial, 67% of patients demonstrated pCRs and none have disease recurrence to date. This treatment was also well tolerated, with investigators observing only 4% grade 3/4 immune-related adverse events (irAEs). Neoadjuvant immunotherapy has a very strong potential to become standard of care for patients with dMMR colon cancer. Thus, researchers believe the future has never been brighter for this patient population.
LES THÉRAPIES CHIRURGICALES
10. Hepatic Artery Infusion Pump (HAIP) Chemotherapy Program – Sunnybrook Odette Cancer Centre (Sept.1/22)
Le programme PPAH est une première au Canada pour les personnes dont le cancer du côlon ou du rectum (cancer colorectal) s'est propagé au foie et ne peut être retiré par une intervention chirurgicale. Le programme implique une approche coordonnée et multidisciplinaire des soins, avec une étroite collaboration entre l'oncologie chirurgicale, l'oncologie médicale (chimiothérapie), la radiologie interventionnelle, la médecine nucléaire et les soins infirmiers en oncologie. La pompe à perfusion de l'artère hépatique (PPAH) est un petit dispositif en forme de disque qui est chirurgicalement implanté juste sous la peau du patient et est relié par un cathéter à l'artère hépatique (principale) du foie. Environ 95 % de la chimiothérapie administrée par cette pompe reste dans le foie, épargnant ainsi le reste du corps des effets secondaires. Les patients reçoivent une chimiothérapie dirigée par PPAH en plus de la chimiothérapie intraveineuse (IV) régulière (chimiothérapie systémique), afin de réduire le nombre et la taille des tumeurs. Drs. Paul Karanicolas and Michael Raphael are the program leads and happy to see patients who may be eligible for the therapy.
Maintenant au centre de cancérologie Odette, le PPAH est utilisé chez les patients atteints d'un cancer colorectal qui s'est propagé au foie et qui ne peut être enlevé chirurgicalement et ne s'est pas propagé à d'autres parties du corps. Les patients qui ont peu (1-5) et de très petites tumeurs dans les poumons peuvent être pris en considération si la maladie pulmonaire est jugée traitable avant le PPAH. Si vous pensez pouvoir bénéficier de cette thérapie et/ou si vous souhaitez en savoir plus sur l'essai clinique, votre oncologue médical ou votre chirurgien peut vous adresser par télécopie au 416-480-6179. Pour plus d'informations sur l'essai clinique PPAH, veuillez cliquer sur le lien fourni ci-dessous
11. Living Donor Liver Transplantation for Unresectable CRC Liver Metastases (Sept.2/22)
Environ la moitié des patients atteints de cancer colorectal (CCR) développent des métastases, généralement au niveau du foie et des poumons. L'ablation chirurgicale des métastases hépatiques (MH) est la seule option de traitement, bien que seulement 20 à 40 % des patients soient candidats à un traitement chirurgical. La thérapie chirurgicale apporte un avantage significatif en termes de survie, avec une survie à 5 ans après résection du foie de 40 à 50 % pour les MH, contre 10 à 20 % pour la chimiothérapie seule. La transplantation du foie (TF) permettrait d'éliminer toute maladie évidente dans les cas où les métastases colorectales sont isolées au foie mais considérées comme non résécables.
While CRC LM is considered a contraindication for LT at most cancer centers, a single center in Oslo, Norway demonstrated a 5-year survival of 56%. A clinical trial sponsored by the University Health Network in Toronto will offer live donor liver transplantation (LDLT) to select patients with unresectable metastases limited to the liver and are non-progressing on standard chemotherapy. Patients will be screened for liver transplant suitability and must also have a healthy living donor come forward for evaluation. Patients who undergo LDLT will be followed for survival, disease-free survival, and quality of life for 5 years and compared to a control group who discontinue the study before transplantation due to reasons other than cancer progression.
LES RADIOTHÉRAPIES/RADIOLOGIE INTERVENTIONNELLE
12. Study Offered at the Odette Cancer Centre to Treat Recurrent Rectal Cancer (Sept.9/21)
Magnetic resonance-guided focused ultrasound (MRg-FU) is a less invasive; outpatient modality being investigated for the thermal treatment of cancer. In MRg-FU, a specially designed transducer is used to focus a beam of low-intensity ultrasound energy into a small volume at a specific target site in the body. MR is used to identify and delineate the tumour, focus the ultrasound beam on the target, and provide a real-time thermal mapping to ensure accurate heating of the designated target with minimal effect to the adjacent healthy tissue. The focused ultrasound beam produces therapeutic hyperthermia (40-42°C) in the target field, causing protein denaturation and cell damage. Currently, there is no prospective clinical data reported on the use of MRg-FU in the setting of recurrent rectal cancer. Recurrent rectal cancer is a vexing clinical problem. Current retreatment protocols have limited efficacy. The addition of hyperthermia to radiation and chemotherapy may enhance the therapeutic response. With recent advances in technology, the investigators hypothesize that MRg-FU is technically feasible and can be safely used in combination with concurrent reirradiation and chemotherapy for the treatment of recurrent rectal cancer without increased side-effects. The study is being offered at the Odette Cancer Centre. Here is the link to the study protocol:
13. Trends in the Incidence of Young-Onset CRC with a Focus on Years Approaching Screening Age (Sept.10/22)
With recent evidence for the increasing risk of young-onset colorectal cancer (yCRC), the objective of this population-based longitudinal study was to evaluate the incidence of yCRC in one-year age increments, particularly focusing on the screening age of 50 years. The study was conducted using linked administrative health databases in British Columbia, Canada including a provincial cancer registry, inpatient/outpatient visits, and vital statistics from January 1, 1986 to December 31, 2016. Researchers calculated the incidence rates per 100,000 at every age from 20 to 60 years and estimated annual percent change in incidence (APCi) of yCRC using joinpoint regression analysis. 3,614 individuals were identified with yCRC (49.9% women). The incidence of CRC steadily rose from 20 to 60 years, with a marked increase from 49 to 50 years. Furthermore, there was a trend of increased incidence of yCRC among women. Analyses stratified by age yielded APCi’s of 2.49% and 0.12% for women aged 30-39 years and 40-49 years, respectively and 2.97% and 1.86% for men. These findings indicate a steady increase over one-year age increments in the risk of yCRC during the years approaching and beyond screening age. These findings highlight the need to raise awareness as well as continue discussions regarding considerations of lowering the screening age.
14. Guardant’s Liquid Biopsy Detects 96% of Early-Stage CRC Cases with a Single Blood Draw (Sept.1/22)
The blood-testing company Guardant Health aims to offer a simpler
Guardant Health’s Lunar-2 liquid biopsy test is designed to catch colorectal cancer (CRC) in its earliest stages and requires only a standard blood draw, offering a less invasive and time-consuming alternative to the current standards for screening. On top of making testing more widely accessible, Guardant’s blood test has also been proven in clinical studies to detect signs of cancer with similar accuracy to colonoscopies and other standard screening methods. Data from a retrospective study of just under 700 patients diagnosed with early-stage colon or rectal cancer showed that Lunar-2 was able to detect stage 1, 2 and 3 CRC with 96% sensitivity and 94% specificity. When the analysis was limited just to those patients with stage 1 or 2 CRC, when signs of cancer are particularly difficult to spot in the blood, Lunar-2’s sensitivity dropped only slightly, to 93%. That number slipped to 90% when the test was used to detect cancer in stage 1 and 2 patients who weren’t yet showing symptoms of the disease. These early results show promise for the liquid biopsy’s potential as an “easy-to-use and highly accurate” alternative to colonoscopies and stool-based tests, especially as the COVID-19 pandemic has led to a drop in clinical visits for cancer screening.
15. Colorectal Sessile Serrated Lesion Detection Using Linked Colour Imaging (Sept.10/22)
Linked colour imaging (LCI) is a novel technique that improves the colour differences between colorectal lesions and the surrounding mucosa. Researchers aimed to compare the efficacy of detecting colorectal sessile serrated lesions (SSL) using LCI with using white light imaging (WLI). A total of 884 patients were involved in the intention-to-treat analysis, with 441 patients in the LCI group and 443 patients in the WLI group. The total polyp detection rate, adenoma detection rate, and SSL detection rate (SDR) were 51.8%, 35.7%, and 8.6%, respectively. The SDR was significantly higher in the LCI group than in the WLI group (11.3% vs 5.9%). Furthermore, LCI significantly increased the number of polyps and adenomas detected per patient, when compared with WLI. In addition, LCI exhibited a dramatically higher detection rate of diminutive and flat lesions. Therefore, LCI is significantly superior to WLI for SSL detection, as well as for polyps and adenomas detection. LCI can be recommended as an appropriate method for routine inspection during colonoscopy. To learn more about the study, please click on the pdf below.
16. Early-Onset CRC Incidence, Staging, and Mortality in Canada: Implications for Population-Based Screening (Sept.13/22)
As the incidence of early-onset colorectal cancer (eoCRC) continues to increase in North America, researchers examined Canadian age-specific trends in CRC incidence and mortality by topography and histology. CRC incidence (2000–2017) and mortality (2000–2018) data were obtained from the Canadian Cancer Registry and Vital Statistics. Among women aged 20–49 years, the incidence of CRC significantly increased from 2000 to 2017 in both the distal colon and rectum, whereas for men aged 20–49 years, the CRC incidence increased in the proximal colon, distal colon, and rectum. Among both men and women aged 20–49 years, the incidence of nonmucinous adenocarcinomas significantly increased, whereas mucinous adenocarcinomas decreased for women and remained stable for men. Adults aged 30 to 49 years, when diagnosed with CRC, had a significantly higher risk of being diagnosed with a late-stage CRC compared with those in the age group of 50–74 years. Rectal cancer mortality increased from 2000 to 2018 in the eoCRC group.
The results of this study indicate that reducing the age of initiation of CRC screening could potentially reduce the incidence and mortality of eoCRC and most notably for rectal cancer; that is, the incidence of topography and histology targets of CRC screening programs are increasing, and mortality is increasing for rectal cancers. However, further research on the effect, cost-effectiveness, and risk prediction for targeted screening within this group is required before making recommendations.
17. Ryan Reynolds Undergoes ‘Life-Saving’ Colonoscopy — And It Was All Caught on Video (Sept.13/22)
While broadcasting his first colonoscopy in order to de-stigmatize the procedure and promote screening, Ryan Reynolds discovered he had a “subtle polyp” on his colon. The actor, 45, and his Wrexham soccer club co-chairman, Rob McElhenney, decided to partner up with Lead From Behind, a colon cancer awareness organization, to encourage people — especially men — to get the procedure when the time comes. In a YouTube video uploaded to Reynolds’ page, the two explained they wanted to prove how the “simple step” can “save lives.” For McElhenney, his doctor revealed they found three polyps that “were not a big deal, but certainly a good thing that [they were] found early and removed.” Reynolds’ polyp, on the right side of his colon, was promptly removed following the procedure. The doctor described how this was essentially life saving for Reynolds as he had no symptoms. To watch the YouTube video, follow the link below.
18. Young Adult CRC Clinic Available at Sunnybrook (Sept.5/22)
A recent study led by the University of Toronto doctors has observed a rise in colorectal cancer (CRC) rates in patients under the age of 50. The study mirrors findings from the U.S., Australia and Europe. The growing CRC rates in young people come after decades of declining rates in people over 50, which have occurred most likely due to increased use of CRC screening (through population-based screening programs) which can identify and remove precancerous polyps. Patients diagnosed under the age of 50 have a unique set of needs, challenges and worries. They are unlike those diagnosed over the age of 50. Le Dr Shady Ashamalla (oncologue chirurgien spécialisé dans le cancer colorectal) et son équipe du Centre des sciences de la santé Sunnybrook comprennent les besoins de cette population de patients.
Le Dr Ashamalla fait partie d'une équipe multidisciplinaire d'experts de La Clinique Du Cancer Colorectal Des Jeunes Adultes who will work with young CRC patients, regardless of disease stage, to create an individualized treatment plan to support each patient through their cancer journey. Their needs and concerns will be addressed as they relate to:
- Préoccupations et questions relatives à la fécondité
- Les jeunes enfants à la maison
- Questions relatives aux données et à l'intimité
- Les défis au travail
- Inquiétudes concernant le cancer héréditaire
- Relations avec la famille et les amis
- Stress psychologique dû à l'un ou à l'ensemble des éléments ci-dessus
L'équipe d'experts est composée de :
- Oncologues (médicaux, chirurgicaux, radiologiques)
- Travailleurs sociaux
- Infirmière navigatrice
Si un patient souhaite être orienté vers Sunnybrook, il peut demander à son médecin traitant ou à son spécialiste de l'orienter vers Sunnybrook via le formulaire d'orientation électronique, accessible via le lien figurant ci-dessous. Une fois l'orientation reçue La Clinique Du Cancer Colorectal Des Jeunes Adultes sera informée si le patient a moins de 50 ans. Un rendez-vous sera alors fixé, au cours duquel le patient rencontrera différents membres de l'équipe afin de répondre à leurs préoccupations spécifiques.
19. CCRAN’s Partnership with “Count Me In” (Sept.1/22)
CCRAN is proud to partner with Count Me In, a nonprofit research initiative, on The Colorectal Cancer Project. This new project is open to anyone in the United States or Canada who has ever been diagnosed with colorectal cancer (CRC). Patients can find out more and join at JoinCountMeIn.org/Colorectal.
Through the project, patients are asked to complete surveys to share information about their experience with CRC, to share biological sample(s), and to allow for the research team to request copies of their medical records. The project team then de-identifies and shares data from these with the entire research community. 10
Every patient’s story holds a piece of the puzzle that can help us better understand CRC. By discovering more about what drives cancer and sharing this data, CCRAN and the Colorectal Cancer Project believe insights can be gained to develop more effective therapies. One of the aims of the project is to reach populations that have been understudied, including individuals who are diagnosed with CRC at a young age, individuals from marginalized communities who have historically been excluded from research, and patients with metastatic CRC. Together, we can accelerate our understanding of CRC. To learn more or sign up to participate, visit JoinCountMeIn.org/Colorectal.
“Count Me In”, a nonprofit cancer research initiative, is inviting all patients across the United States and Canada who have ever been diagnosed with colorectal cancer (CRC) to participate in research and help drive new discoveries related to this disease. The Colorectal Cancer Project will enable patients to easily share their samples, health information and personal lived experiences directly with researchers in order to accelerate the pace of research.
Patients who have been diagnosed with CRC at any point in their lives can join the project by visiting JoinCountMeIn.org/colorectal. From there, patients will be invited to share information about their experience through surveys and to provide access to medical records as well as saliva samples and optional blood, stool, and/or stored tissue samples for study and analysis. Researchers from the Broad Institute of MIT and Harvard and Dana-Farber Cancer Institute use this information to generate databases of clinical, genomic, molecular, and patient-reported data that is then de-identified and shared with researchers everywhere. To date, more than 9,000 patients with different cancers have joined Count Me In and shared their data. “We still do not know why there is an alarming rise in CRC in young adults”, said Andrea Cercek, MD Co-Director, Center for Young Onset Colorectal and Gastrointestinal Cancers Memorial Sloan Kettering Cancer Center and co-scientific leader of the Colorectal Cancer Project. “What we do know is that this is a global phenomenon that affects otherwise healthy individuals with no known risk factors. The Colorectal Cancer Project will provide researchers important information that will lead to a better understanding of this disease.”
Over 250 patients have joined the Colorectal Cancer Project since the launch in fall 2021. Every patient that joins the Colorectal Cancer Project enables us to learn more about colorectal cancer. Pts diagnosed at any age, whether newly diagnosed or years from their diagnosis, can enroll. If you have ever been diagnosed with colorectal cancer, you can visit JoinCountMeIn.org/Colorectal to enroll and have a direct impact on research and future treatment strategies.
20. Patients and Caregivers Needed to Help Shape Early Research for a CRC Therapy (Sept.10/22)
21. Under 50 National Colorectal Cancer Information/Support Group Now Available at CCRAN! (Sept.2/22)
ARE YOU AN EARLY AGE ONSET (<50 YEARS) COLORECTAL CANCER PATIENT OR CAREGIVER LOOKING FOR INFORMATION OR SUPPORT?
Meet Hayley Painter R.N. and proud survivor of metastatic colorectal cancer!
Hayley will be assuming the lead on CCRAN’s Monthly National Under 50 Colorectal Cancer Information/Support Group Meetings!
When: Every third Sunday of the month
Time: 7:00 – 9:00 p.m.
Where: Via Zoom
To Register: Hayley.email@example.com
Please join Hayley as she will deliver important treatment updates and provide optimal support to each patient in their colorectal cancer journey at these support group meetings. To register for the meeting, please contact Hayley using the email provided above.
NUTRITION/MODE DE VIE SAIN
22. Exercise for Cancer to Enhance Living Well (EXCEL) Study (Sept.11/22)
Exercise for Cancer to Enhance Living Well (EXCEL) is a 5-year Canada-wide project, which offers free, 12-week exercise classes designed specifically for individuals undergoing or recovering from cancer treatment. This project will increase the accessibility of exercise programs for rural and remote cancer survivors. Physical activity can help overcome treatment-related side effects such as fatigue and pain, improve mental health by reducing anxiety and depression, and improve overall quality of life for individuals living with and beyond cancer. Studies show that physical activity may even reduce the risk of recurrence for some cancers.
Join us on August 21e at CCRAN’s National Online Support Group Meeting to learn more about the benefits of physical activity for individuals living with and beyond colorectal cancer (CRC)), discuss tips for becoming and staying active, plan ahead to move more, and discover a wide range of free cancer-specific exercise resources or programs. The session will be led by Chad Wagoner, a Clinical Exercise Physiologist with the American College of Sports Medicine with a PhD in Human Movement Science from the University of North Carolina at Chapel Hill. His research centers around the development and evaluation of implementation for community-based exercise oncology programs in addition to examining the role of Clinical Exercise Physiologists within clinical cancer care to better connect those living with cancer to appropriate exercise oncology resources.
To learn more about the EXCEL study:
To hear about participant experiences: https://www.youtube.com/watch?v=c01oo4Yd3oA
23. Ultra-processed Foods Linked to Cancer and Early Death (Sept.1/22)
According to two new, large-scale studies of people in the United States and Italy, eating a lot of ultra-processed foods significantly increases men’s risk of colorectal cancer (CRC) and can lead to heart disease and early death in both men and women. Ultra-processed foods include prepackaged soups, sauces, frozen pizza, ready-to-eat meals and pleasure foods such as hot dogs, sausages, french fries, sodas, store-bought cookies, cakes, candies, doughnuts, ice cream and many more.
The U.S.-based study examined the diets of over 200,000 men and women for up to 28 years and found a link between ultra-processed foods and CRC in men, but not women. The study found that men in the highest quintile of ultra-processed food consumption, compared those in the lowest quintile, had a 29% higher risk of developing CRC. Reasons for such a sex difference are still unknown, but may involve the different roles that obesity, sex hormones, and metabolic hormones play in men versus women. The study did find that eating a “higher consumption of ultra-processed dairy foods — such as yogurt — was associated with a lower risk of CRC in women.
The second study followed more than 22,000 people for a dozen years in the Molise region of Italy. The study, which began in March 2005, was designed to assess risk factors for cancer as well as heart and brain disease. The analysis compared the role of nutrient-poor foods — such as foods high in sugar and saturated or trans-fats — versus ultra-processed foods in the development of chronic disease and early death. The researchers discovered that ultra-processed foods were paramount to define the risk of mortality. This suggests that the increased risk of mortality is not due directly (or exclusively) to the poor nutritional quality of some products, but rather to the fact that these foods are mostly ultra-processed.
MISES À JOUR COVID-19
24. Could you be at high risk of severe COVID-19? (Aug.29/22)
There are many factors that can put you at high risk of developing severe COVID-19 if you get infected. You may be at high risk if any of the factors below describe you. If you have a risk factor listed below, you are more likely than someone with no risk factors to have worsening symptoms that could lead to hospitalization or even death.
With that it is important to be ready to ACT fast:
1. Assess yourself for COVID-19 symptom
2. Confirm through COVID-19 testing as soon as possible
3. Talk to your healthcare provider to seek treatment
25. Frequently Asked Questions for COVID-19
Q: What is COVID-19 (or novel Coronavirus Disease – 19)?
A: Coronaviruses are a large family of viruses that can cause illnesses in humans and animals. Coronaviruses can cause illnesses that range in severity from the common cold to more severe diseases such as Severe Acute Respiratory Syndrome (SARS) and most recently, COVID-19. COVID-19 or novel coronavirus originated from an outbreak in Wuhan, China in December 2019. The most common symptoms associated with COVID-19 can include fever, fatigue, and a dry cough. Though additional symptoms have now been linked with the disease, which may include aches and pains, nasal congestion, runny nose, sore throat, diarrhea, skin rash and vomiting. It is also possible to become infected with COVID-19 and not experience any symptoms or feeling ill. The spread of COVID-19 is mainly through the transmission of droplets from the nose or mouth when a person coughs, exhales or sneezes. These droplets land on surfaces around a nearby person. COVID-19 can be transmitted to that nearby person who may end up touching the surface contaminated with COVID-19 and then end up touching their nose, mouth, or eyes. A person can also contract COVID-19 through inhaling these droplets from someone with COVID-19. Although research is still ongoing, it is important to note that older populations (over the age of 65), those with a compromised immune system and those with pre-existing conditions including heart disease, high blood pressure, lung disease, diabetes or cancer may be at a higher risk of severe illness due to COVID-19.
Q: What can I do to avoid getting Coronavirus?
A: There are various ways in which we can reduce our risk of contracting COVID-19. Below are some measures suggested by the World Health Organization
1. Keep at least 2 metres (or 6 feet) between yourself and other people. This will reduce the risk of inhaling droplets from those infected with COVID-19.
2. Regularly clean your hands for at least 20 seconds with warm water and soap, or an alcohol-based hand rub. This will kill any viruses on your hands.
3. Avoid touching your eyes, nose and mouth. If the virus is on your hands, it can enter the body through these areas.
4. Follow good respiratory hygiene by covering your mouth and nose with a tissue or elbow when you cough and sneeze. This prevents the droplets from settling on surfaces or being released into the air around you.
5. Stay home as much as possible, especially if you are feeling unwell. If you think you may have the Coronavirus, please see “What should I do if I think I have Coronavirus?” section.
6. Please wear a face covering or mask in public when physical distancing is not possible.
Y a-t-il des précautions particulières que les personnes atteintes d'un cancer peuvent prendre ?
R : Les personnes atteintes de cancer (et d'autres maladies chroniques telles que les maladies cardiaques, le diabète, l'hypertension et les maladies pulmonaires) sont plus exposées à une maladie grave en raison de la COVID-19, le cancer étant considéré comme un problème de santé préexistant. Certains traitements contre le cancer, notamment la chimiothérapie, les radiations et la chirurgie, peuvent affaiblir le système immunitaire, ce qui rend l'organisme plus difficile à combattre les infections et les virus, comme le Coronavirus. Il est important de suivre avec diligence les recommandations de l'Organisation mondiale de la santé ci-dessus pour réduire le risque de contracter le COVID-19. Si vous avez des inquiétudes quant à votre risque, il est préférable de contacter votre médecin ou votre équipe de soins.
Y a-t-il des changements en ce qui concerne mes visites médicales liées au cancer ? Chaque patient et chaque plan de traitement étant uniques, il est toujours préférable de contacter votre prestataire de soins de santé pour obtenir des informations actualisées sur votre plan de traitement. Dans certains cas, il est possible de retarder le traitement du cancer jusqu'à ce que le risque de pandémie ait diminué. Dans d'autres cas, il peut être sûr de se rendre dans une clinique distincte de celle où sont traités les patients COVID-19. Les options de traitement oral pourraient être prescrites par votre prestataire de soins de manière virtuelle, sans qu'il soit nécessaire de se rendre à la clinique. Enfin, certains rendez-vous ou discussions de suivi pourraient être organisés virtuellement (via skype ou zoom par exemple) ou par téléphone pour minimiser votre risque. Comme nous le savons, les conditions et les protocoles changent quotidiennement en raison de la nature de l'épidémie de COVID-19 et varient en fonction du lieu, par conséquent, la meilleure première étape consiste à demander conseil à votre prestataire de soins.
Si vous souhaitez contacter votre agence locale de santé publique, veuillez voir ci-dessous.
Informations COVID-19 pour Alberta
Les médias sociaux : Instagram @albertahealthservices, Facebook @albertahealthservices, Twitter @GoAHealth
Numéro de téléphone : 811
Informations COVID-19 pour Colombie-Britannique
Les médias sociaux : Facebook @ImmunizeBC, Twitter @CDCofBC
Numéro de téléphone : 811
Informations COVID-19 pour Manitoba
Les médias sociaux : Facebook @manitobagovernment, Twitter @mbgov
Numéro de téléphone : 1-888-315-9257
Informations COVID-19 pour Nouveau-Brunswick
Les médias sociaux : Facebook @GovNB, Twitter @Gov_NB, Instagram @gnbca
Numéro de téléphone : 811
Terre-Neuve et Labrador
Informations COVID-19 pour Terre-Neuve-et-Labrador
Les médias sociaux : Facebook @GovNL, Twitter @GovNL, Instagram @govnlsocial
Numéro de téléphone : 811 ou 1-888-709-2929
Territoires du Nord-Ouest
Informations COVID-19 pour Territoires du Nord-Ouest
Les médias sociaux : Facebook @NTHSSA
Numéro de téléphone : 811
Informations COVID-19 pour Nouvelle-Écosse
Les médias sociaux : Facebook @NovaScotiaHealthAuthority , Twitter @healthns, Instagram @novascotiahealthauthority
Numéro de téléphone : 811
Informations COVID-19 pour Nunavut
Les médias sociaux : Facebook @GovofNunavut , Twitter @GovofNunavut, Instagram @gouvernement du Nunavut
Numéro de téléphone : 1-888-975-8601
Informations COVID-19 pour Ontario
Les médias sociaux : Facebook @ONThealth, Twitter @ONThealth , Instagram @ongov
Numéro de téléphone : 1-866-797-0000
Informations COVID-19 pour Île-du-Prince-Édouard
Social media: Facebook @GovPe, Twitter @InfoPEI, 16
Informations COVID-19 pour Québec
Les médias sociaux : Facebook @GouvQc, Twitter @sante_qc
Numéro de téléphone : 1-877-644-4545
Informations COVID-19 pour Saskatchewan
Les médias sociaux : Facebook @SKGov, Twitter @SKGov
Numéro de téléphone : 811
Informations COVID-19 pour Yukon
Les médias sociaux : Facebook @yukonhss, Twitter @hssyukon
Numéro de téléphone : 811